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a case for advanced imaging techniques?
Amy S Oxentenko1 and Thomas C Smyrk2*Abstract
Background: Lynch syndrome confers increased risk for various malignancies, including colorectal cancer.
Colonoscopic surveillance programs have led to reduced incidence of colorectal cancer and reduced mortality from
colorectal cancer. Colonoscopy every 1–2 years beginning at age 20–25, or 10 years earlier than the first diagnosis
of colorectal cancer in a family, with annual colonoscopy after age 40, is the recommended management for
mutation carriers. Screening programs have reduced colon cancer mortality, but interval cancers may occur.
Case presentation: We describe a 48-year-old woman with Lynch syndrome who was found to have an adenoma
with invasive colorectal cancer within one year after a normal colonoscopy.
Conclusion: Our patient illustrates two current concepts about Lynch syndrome: 1) adenomas are the cancer
precursor and 2) such adenomas may be “aggressive,” in the sense that the adenoma progresses more readily and
more rapidly to carcinoma in this setting compared to usual colorectal adenomas. Our patient’s resected tumor
invaded only into submucosa and all lymph nodes were negative; in that sense, she represents a success for annual
colonoscopic surveillance. Still, this case does raise the question of whether advanced imaging techniques are
advisable for surveillance colonoscopy in these high-risk patients.
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Lynch syndrome is defined as the presence of a germline
mutation in a DNA mismatch repair gene [1]. Mutation
carriers have increased risk for various malignancies, in-
cluding carcinomas of the colorectum (CRC), endomet-
rium, ovary, small bowel, stomach, biliary tract, bladder,
ureter and renal pelvis [2]. When a mutation is docu-
mented in an affected individual, genetic counseling and
mutation analysis should be offered to related family
members. Mutation carriers face a range of difficult
decisions regarding prophylaxis and surveillance.
Prophylactic hysterectomy, for example, offers low mor-
bidity and guaranteed protection against endometrial
cancer, but may conflict with the desire to bear children
[3]. Prophylactic colectomy is also an option, but regular* Correspondence: smyrk.thomas@mayo.edu
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distribution, and reproduction in any mediumcolonoscopic examination is safe and effective and is the
favored approach for most patients [4].
Colonoscopic surveillance should begin at age 20–25.
There has been debate about the optimal timing for
examinations, with the recommended interval narrow-
ing recently from three years to two years and finally
to the current preference for colonoscopy every one to
two years until age 40, with yearly colonoscopy there-
after [5]. The rationale for the one-year timeframe is
that interval cancers have been described in patients
being examined every two or three years, probably in
part because the precursor lesion for CRC in Lynch
syndrome – the adenoma – progresses through the
adenoma-carcinoma sequence more rapidly than a
sporadic adenoma.
We describe a young woman with known Lynch
syndrome who presented for her surveillance colono-
scopic examination and was discovered to have a right-
sided CRC arising in a tubular adenoma, one year after a
normal examination.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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The patient is a 48-year-old female with known Lynch
syndrome. Her father, the proband, had primary CRC at
age 43, 51 and 69, then a jejunal adenocarcinoma at age
71. He was found to have a truncating mutation on
MLH1 (IVS7-2A>G) and a separate missense mutation
of uncertain significance (V716M). The family tree is re-
plete with other malignancies characteristic of Lynch
syndrome (Figure 1).
Based on family history alone, the patient began colo-
noscopic evaluations every five years beginning at age
18. She had genetic testing at age 42 and was found to
carry both the deleterious truncating mutation and the
missense mutation. She underwent prophylactic hyster-
ectomy and bilateral salpingo-oophorectomy, and began
a program of annual colonoscopy in 2003.
In September 2009, the patient established her can-
cer surveillance at our institution. Her past medical
history was significant only for migraine headaches,
hypothyroidism and endometriosis. She was married,
with no children, had no tobacco history and infre-
quent alcohol use. Her physical examination was un-
remarkable. Laboratory studies at that time were all
within normal limits, including hemoglobin of 12.3 g/
dL. Full colonoscopy with intensive inspection was
performed and was negative, with good bowel prepar-
ation noted. The remainder of her tests, includingFigure 1 Family pedigree in the described patient with Lynch syndro
CA= cancer; ? = unknown history.mammography, upper endoscopy, CT enteroclysis and
urine cytology were all negative or normal. The pa-
tient had no symptoms referable to her lower GI tract
over the ensuing year. At her September 2010 exam,
laboratory studies revealed hemoglobin of 11.8 g/dL
with a mean corpuscular volume of 81.5 fL (normal
81.6-98.3 fL). At colonoscopy, the endoscopist noted
“a 1.2 cm, malignant-appearing flat lesion on top of a
fold” in the ascending colon (Figure 2). Biopsy showed
a tubular adenoma adjacent to a moderately differen-
tiated adenocarcinoma. Immunohistochemistry for
MLH1 demonstrated loss of expression in both the
adenoma and the carcinoma (Figure 3). Her carci-
noembryonic antigen (CEA) level was 0.5 ng/mL (nor-
mal ≤ 3.0 ng/mL). Eight days later, she had a hand-
assisted subtotal colectomy with ileorectostomy. The
resection specimen contained a 1.8 cm, moderately
differentiated adenocarcinoma arising 7.5 cm distal to
the ileocecal valve. An adenoma extended from one
edge of the cancer for a distance of 9 mm. The
tumor invaded into the submucosa but not into the
muscularis propria, and multiple (49) lymph nodes
were negative, making this a T1N0 lesion. There were
no other mucosal lesions. The post-operative course
was uneventful. She was discharged 7 days after her
operation. Follow-up examination and surveillance
testing one year later were unremarkable.me. Arrow indicates the presented patient. CRC= colorectal cancer;
Figure 2 Endoscopic photo demonstrating a 1.2 cm lesion on
top of a fold in the ascending colon.
Figure 3 a) Biopsy of mucosal lesion, showing adenoma (right)
and carcinoma (left). (Original magnification 40x) b)
Immunohistochemistry for MLH1, performed on the endoscopic
biopsy. The adenoma and the cancer both show loss of expression.
Non-neoplastic crypts in the center of the field show the expected
nuclear staining. (Original magnification 100x).
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Lynch syndrome is not rare. The magnitude of its con-
tribution to the total CRC burden has been debated,
with some estimates as high as 6% [6] and others as low
as 0.86% [7]. Current estimates are that approximately
3% of all CRCs arise in the setting of Lynch syndrome
[8,9]. Surveillance programs conducted in Europe during
the late 20th century put the lifetime risk for CRC at 70-
80% [10,11]. That number has been a matter of some
controversy.
A large study which applied corrections for ascertain-
ment bias calculated a lifetime CRC risk of only 27% for
men and 22% for women [12]. But other large studies,
also controlled for ascertainment bias, have arrived at
lifetime CRC risks of 45-66% for men and 38-43% for
women [13]. In some reports, the risk for CRC is modu-
lated by the gene involved (higher for MLH1) [13], sex
(higher for men), and possibly environmental exposures
(risk reduced by dietary fruit and fiber, increased by
cigarette smoking) [14]. It is also likely that the specific
mutation influences cancer risk; indeed, a criticism of
one early risk study [11] was that the large majority of
the study patients carried the same founder mutation on
MLH1, and were thus not representative of the full
spectrum of Lynch syndrome patients. As more data is
accumulated, it should become possible to individualize
patient risk based on all of the above factors.
Adenoma is the precursor lesion for CRC in Lynch
syndrome. The original term “hereditary non-polyposis
colorectal carcinoma (HNPCC)” was coined to separate
the condition from polyp-forming syndromes, particu-
larly familial adenomatous polyposis. While patients
with Lynch syndrome don’t have large numbers of aden-
omas, they clearly form them more readily than the gen-
eral population [15,16]. Mecklin et al. found the
cumulative incident risk for adenoma to be 68% in men
and 48% in women by age 60 [16]. The authors usedtheir data to calculate that 40% of men and 30% of
women have a colorectal neoplasm of some kind by age
40. In contrast, only 1-2% of the general population has
an adenoma at that age [17].
Regular endoscopic surveillance aimed at discovering
and removing adenomas reduces mortality from CRC in
Lynch syndrome. A controlled trial among 252 Finnish
patients deemed to be at 50% risk of CRC by virtue of
family history demonstrated a 62% reduction in CRC
among those who had regular surveillance compared to
those who refused surveillance [18]. Tumor stage was
significantly more favorable in the study group, and
none of 133 patients under surveillance died of CRC,
compared to 9 of 119 (8%) of controls. More recently,
de Jong et al. described a long-term surveillance pro-
gram in the Netherlands and showed a 70% reduction in
the standard mortality ratio for CRC during the surveil-
lance era [19].
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Lynch syndrome can progress to carcinoma more rap-
idly than sporadic adenomas. Immunohistochemistry
generally shows loss of staining for mismatch repair pro-
teins in adenomas from Lynch syndrome patients
[20,21], meaning that they have already lost the ability to
repair DNA mismatches. The very rapid rate at which
mutations accumulate in this setting provides a molecu-
lar mechanism for the “aggressive adenoma” concept
proposed many years ago [22-24].
A recent study involving 54 patients with known
mutations in MLH1 or MSH2 gives strong observational
support to the aggressive adenoma idea [25]. Surveil-
lance by colonoscopy every 1–2 years over a mean fol-
low-up period of 9.3 years led to the detection of 112
adenomas and 31 CRC. The authors calculated a polyp
dwell time (the time interval from normal mucosa to
CRC) of 35.2 +/− 22.3 months. Admittedly, the standard
deviations are large, but the numbers are strikingly
shorter that the 10 years estimated for the adenoma-car-
cinoma sequence in sporadic CRC [26].
What is the proper surveillance interval? Numerous
large-scale surveillance programs support the notion of
rapid carcinogenesis. Jarvinen et al. achieved their reduc-
tion in CRC using colonoscopy every three years, but
interval cancers did occur under that strategy and others
like it [16,18,27]. Vasen et al. showed that for carriers of
MLH1 or MSH2 mutations, a surveillance interval of 1–
2 years reduced CRC risk compared to 3-year intervals
[28]. A multicenter cohort study from Germany found
good compliance to a regimen of annual surveillance
colonoscopy among 1126 individuals; that prospective
study, using standard video colonoscopy, detected 43 in-
cident CRC, 19 of which had been preceded within
12 months by a normal colonoscopy [29].
Does our patient’s tumor represent a rapidly developing
malignancy or a missed polyp (or both)? Missed polyps
are an unfortunate reality; one prospective multicenter
study found a miss rate for adenomas of 20% [30]. Look-
ing specifically at Lynch syndrome, Stoffel et al. found a
stunningly high adenoma miss rate of 55% when standard
colonoscopy was followed by a tandem second exam with
chromoendoscopy and/or intensive inspection [31]. The
fact that the neoplasia in Lynch syndrome is often right-
sided might contribute to this; the polyp dwell time in
Edelstein’s study was shorter for right-sided lesions
(28.7 months) than for those in the left colon (43.6 months)
[25]. The differences were not statistically significant,
but they do hint that both rapid tumor growth and
missed adenomas contribute to the problem of interval
cancers in Lynch syndrome. The issue of rapid tumor
growth can be addressed by emphasizing the importance
to patients and providers of adhering to a strict annual
surveillance program. Accountability to various qualitymetrics, such as withdrawal time and adenoma detection
rates, could help decrease missed adenomas by endosco-
pists. Finally, risk variations within families could conceiv-
able alter the aggressiveness with which one pursues
surveillance; our patient’s sister was diagnosed with a
T3N0M0 colon cancer one year after a normal annual sur-
veillance colonoscopy, having received annual examina-
tions over a number of years at our institution as well.
While it is possible that there could have been missed
lesions in both cases, we think it more likely that some-
thing in the genetic/environmental background of this
family makes them avid carcinoma formers.
Our patient was not in a research study. Her colonos-
copies were conducted by experienced gastroenterolo-
gists who were aware of her mutation status. She was
given a split-dosed bowel preparation for both her 2009
and 2010 colonoscopies, and intensive inspection was
performed; narrow-band imaging was available, but no
additional visualization techniques such as chromoendo-
scopy were used. Standard video colonoscopy has been
the technique of choice in large-scale surveillance pro-
grams [29] and current surveillance recommendations
do not include the use of enhanced visualization meth-
ods [4]. Although Stoffel et al. reported that the high ad-
enoma miss rate could be corrected by EITHER
chromoendoscopy or intensive inspection at the second-
look procedure [31], others have found that the use of
chromoendoscopy may indeed enhance adenoma detec-
tion compared to colonoscopies performed with stand-
ard white light or narrow band imaging technique [32].
Additional studies are required to see whether adding
chromoendoscopy to standard intensive inspection in
patients with Lynch syndrome confers reproducible
benefit, perhaps supporting its inclusion in future cancer
surveillance guidelines for this patient population.
This report highlights several features of Lynch syn-
drome. First, individuals carrying deleterious mutations
in a DNA mismatch repair gene (MLH1, MSH2, MSH6,
PMS2) deserve annual colonoscopic examinations with a
careful search for, and removal of, all mucosal lesions.
Second, adenoma is the precursor lesion for CRC in
Lynch syndrome. Such adenomas are “aggressive,” in the
sense that the time from normal mucosa to CRC is
much shorter than in the general population; close fol-
low-up of patients with Lynch syndrome is essential for
this reason. Next, screening colonoscopy works, and it
works in the setting of routine clinical practice. There
has been some concern that lessons learned from mass
screening programs might not transfer to daily practice
[33]. However, our patient and multiple other members
of her family are cared for by a single gastroenterologist
who does not have a specific research interest in Lynch
syndrome. It may take encouragement to get patients
who feel well to adhere to the somewhat onerous
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part of a successful physician-patient relationship, and
its rewards are illustrated by this report. Finally, the in-
corporation of advanced imaging techniques into sur-
veillance guidelines for patients with Lynch syndrome
undergoing annual colonoscopic examinations will likely
evolve if additional studies can demonstrate consistent
benefit, which may be especially important in patients
with high-risk features.
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